Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

References

• Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142:819–826.
   PubMed Web of Science ®Google Scholar
• Rajan SK Thrombotic thrombocytopenic purpura. BMJ best practice topics. 2017. [cited 2019 Apr]. Available from: https://bestpractice.bmj.com/topics/en-gb/715
   Google Scholar
• Reese JA, Muthurajah DS, Kremer Hovinga JA, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013;60:1676–1682.
   PubMed Web of Science ®Google Scholar
• Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594.
   PubMed Web of Science ®Google Scholar
• Moake JL. Thrombotic thrombocytopenic purpura: the systemic clumping “plague”. Annu Rev Med. 2002;53:75–88.
   PubMed Web of Science ®Google Scholar
• Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129:2836–2846.
   PubMed Web of Science ®Google Scholar
• Kremer Hovinga JA, Coppo P, Lammle B, et al. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017;3:17020.
   PubMed Web of Science ®Google Scholar
• Coppo P. Management of thrombotic thrombocytopenic purpura. Transfus Clin Biol. 2017;24:148–153.
   PubMed Web of Science ®Google Scholar
• Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2019;3:26–37.
   PubMed Web of Science ®Google Scholar
• Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group. N Engl J Med. 1991;325:393–397.
   PubMed Web of Science ®Google Scholar
• Han B, Page EE, Stewart LM, et al. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol. 2015;90:709–714.
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Boelle PY, Baudin B, et al. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. experience of the French thrombotic microangiopathies reference center. J Thromb Haemost. 2015;13:293–302.
   PubMed Web of Science ®Google Scholar
• Chemnitz JM, Uener J, Hallek M, et al. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol. 2010;89:1029–1033.
   PubMed Web of Science ®Google Scholar
• Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125:3860–3867.
   PubMed Web of Science ®Google Scholar
• Coppo P, Veyradier A. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med. 2012;41:e163–176.
   PubMedGoogle Scholar
• Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013;122:2023–2029, quiz 2142.
   PubMed Web of Science ®Google Scholar
• Falter T, Alber KJ, Scharrer I. Long term outcome and sequelae in patients after acute thrombotic thrombocytopenic purpura episodes. Hamostaseologie. 2013;33:113–120.
   PubMed Web of Science ®Google Scholar
• Thejeel B, Garg AX, Clark WF, et al. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review. Am J Hematol. 2016;91:623–630.
   PubMed Web of Science ®Google Scholar
• Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118:757–765.
   PubMed Web of Science ®Google Scholar
• Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010;91:1–19.
   PubMed Web of Science ®Google Scholar
• Springer TA. von Willebrand factor, jedi knight of the bloodstream. Blood. 2014;124:1412–1425.
   PubMed Web of Science ®Google Scholar
• Luo GP, Ni B, Yang X, et al. von Willebrand factor: more than a regulator of hemostasis and thrombosis. Acta Haematol. 2012;128:158–169.
   PubMed Web of Science ®Google Scholar
• Huizinga EG, Tsuji S, Romijn RA, et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002;297:1176–1179.
   PubMed Web of Science ®Google Scholar
• Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125:2019–2028.
   PubMed Web of Science ®Google Scholar
• Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–494.
   PubMed Web of Science ®Google Scholar
• Crawley JT, de Groot R, Xiang Y, et al. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 2011;118:3212–3221.
   PubMed Web of Science ®Google Scholar
• Knöbl P. Thrombotic thrombocytopenic purpura. Memo. 2018;11:220–226.
   PubMedGoogle Scholar
• Holz JB. The TITAN trial–assessing the efficacy and safety of an anti-von Willebrand factor nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci. 2012;46:343–346.
   PubMed Web of Science ®Google Scholar
• Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92:3983–3996.
   PubMed Web of Science ®Google Scholar
• Bioequivalence of liquid and reconstituted lyophilized subcutaneous formulations of caplacizumab. [cited 2019 Apr]. Available from: https://ClinicalTrials.gov/show/NCT02189733.
   Google Scholar
• Caplacizumab single and multiple dose study in healthy Japanese and white subjects. [cited 2019 Apr]. Available from: https://ClinicalTrials.gov/show/NCT03172208.
   Google Scholar
• Study to assess efficacy and safety of anti-von Willebrand factor nanobody in patients with acquired Thrombotic Thrombocytopenic Purpura (TTP). [cited 2019 Apr]. Available from: https://ClinicalTrials.gov/show/NCT01151423.
   Google Scholar
• Phase III trial with caplacizumab in patients with acquired thrombotic thrombocytopenic purpura. [cited 2019 Apr]. Available from: https://ClinicalTrials.gov/show/NCT02553317.
   Google Scholar
• Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335–346.
   PubMed Web of Science ®Google Scholar
• Howard MA, Firkin BG. Ristocetin: a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh. 1971;26:362–369.
   PubMedGoogle Scholar
• Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374:511–522.
   PubMed Web of Science ®Google Scholar
• Bergstrand M, Hansson E, Sargentini-Maier M. Caplacizumab dosing rational in aTTP patients supported by mechanism based PKPD modelling. Page. 2019;2019(Abstract):8800.
   Google Scholar
• van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood. 2008;112:1704–1712.
   PubMed Web of Science ®Google Scholar
• Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol. 2012;52:54S–62S.
   PubMed Web of Science ®Google Scholar
• Flanders MM, Crist RA, Roberts WL, et al. Pediatric reference intervals for seven common coagulation assays. Clin Chem. 2005;51:1738–1742.
   PubMed Web of Science ®Google Scholar
• Sosothikul D, Seksarn P, Lusher JM. Pediatric reference values for molecular markers in hemostasis. J Pediatr Hematol Oncol. 2007;29:19–22.
   PubMed Web of Science ®Google Scholar
• Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323–335.
   PubMed Web of Science ®Google Scholar
• Masias C, Cataland SR. Novel therapies in thrombotic thrombocytopenic purpura. Res Pract Thromb Haemost. 2018;2:19–26.
   PubMed Web of Science ®Google Scholar
• Furlan M. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. Adv Nephrol Necker Hosp. 2000;30:71–81.
   PubMedGoogle Scholar